As Biotechnology companies, Regulus Therapeutics Inc. (NASDAQ:RGLS) and ARCA biopharma Inc. (NASDAQ:ABIO) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regulus Therapeutics Inc.	N/A	161.16	48.71M	-2.11	0.00
ARCA biopharma Inc.	N/A	0.00	7.93M	-0.82	0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Regulus Therapeutics Inc. and ARCA biopharma Inc.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

	Net Margins	Return on Equity	Return on Assets
Regulus Therapeutics Inc.	0.00%	-311.5%	-97.6%
ARCA biopharma Inc.	0.00%	0%	0%

Volatility & Risk

Regulus Therapeutics Inc.’s current beta is 2.29 and it happens to be 129.00% more volatile than Standard & Poor’s 500. ARCA biopharma Inc. has a 2.08 beta and it is 108.00% more volatile than Standard & Poor’s 500.

Liquidity

1 and 1 are the respective Current Ratio and a Quick Ratio of Regulus Therapeutics Inc. Its rival ARCA biopharma Inc.’s Current and Quick Ratios are 8.5 and 8.5 respectively. ARCA biopharma Inc. has a better chance of clearing its pay short and long-term debts than Regulus Therapeutics Inc.

Analyst Ratings

The Ratings and Recommendations for Regulus Therapeutics Inc. and ARCA biopharma Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Regulus Therapeutics Inc.	0	2	0	2.00
ARCA biopharma Inc.	0	0	0	0.00

Regulus Therapeutics Inc.’s upside potential is 62.04% at a $1.75 consensus target price.

Insider & Institutional Ownership

The shares of both Regulus Therapeutics Inc. and ARCA biopharma Inc. are owned by institutional investors at 31.3% and 15.4% respectively. Insiders owned 13.2% of Regulus Therapeutics Inc. shares. Competitively, 0.89% are ARCA biopharma Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Regulus Therapeutics Inc.	8.41%	23.4%	-27.04%	-59.08%	-91.05%	24.65%
ARCA biopharma Inc.	5.75%	9.55%	-15.6%	-24.74%	-36.11%	37.93%

For the past year Regulus Therapeutics Inc. was less bullish than ARCA biopharma Inc.

Summary

On 6 of the 8 factors ARCA biopharma Inc. beats Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.